In a new effort to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, CND has launched a targeted print and digital campaign across several top neurology journals and websites.
A core value of CND Life Sciences is putting patients first. We understand that there’s a patient behind every Syn-One Test™ we perform. That’s why we’re launching the Patient Matters video series—hosted by former CNN anchor Daryn Kagan—to bring those patients’ stories to the forefront and demonstrate the importance of the Syn-One Test in helping clinicians make an objective and accurate diagnosis.
In the November 2020 issue of Movement Disorders, Dommershuijsen and his fellow researchers in the Netherlands wrote an excellent editorial on the ethical considerations of screening for rapid eye movement sleep behavior disorder (RBD) in the healthy general population. I wanted to use this blog to discuss why this question is such an important one to consider as discoveries in the alpha-synucleinopathies continue to advance.
It is 4:30 AM and you are sound asleep. Suddenly your significant other screams and starts punching and kicking you. You struggle to protect yourself and don’t understand what is happening. Your partner is very confused and extremely upset that they may have hurt you. This frightening scenario is estimated to occur in approximately 1% of the population, so this type of event happens in millions of households every night.
The identification of a reliable biomarker in neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s…